一线培美曲塞联合艾迪注射液治疗老年晚期肺腺癌的临床观察

Clinical observation of pemetrexed or pemetrexed combined with aidi injection as first-line treatment of advanced lung adenocarcinoma for elderly patients

目的比较一线培美曲塞和培美曲塞联合艾迪注射液治疗老年晚期肺腺癌患者的疗效和不良反应。方法老年晚期肺腺癌患者共61例,随机分为治疗组和对照组。治疗组31例,培美曲塞500mg/m2,第1天静脉滴注,每3～4周为1个周期;艾迪50ml,静脉滴注,共15d;对照组30例,单药培美曲塞500mg/m2,第1天静脉滴注,3～4周为1个疗程。结果治疗组和对照组有效率(RR)分别为45.2%、43.3%,肿瘤控制率(TGCR)分别为71.0%、66.7%。两组不良反应均可耐受,治疗组耐受性及生存质量均高于对照组(P<0.05)。结论老年晚期肺腺癌患者可从单药一线培美曲塞中获益;培美曲塞联合艾迪注射液可减轻化疗相关不良反应,改善患者的生存质量。

Objective To observe the efficacy and toxic reaction of pemetrexed or pemetrexed combined with Aidi injection as first-line treatment of advanced lung adenocarcinoma for elderly patients.Methods Sixty-one elderly patients with advanced lung adenocarcinoma were divided into treatment and control groups randomly.In treatment group,31 cases received pemetrexed at a dose of 500 mg/m2 on days 1,repeated every 3-4 weeks for one recycles;in the same time of pemetreaed chemotherapy,Aidi injection（50 ml）was given intravenously on day 1-15.While in control group,30 cases were only treated with pemetreaed.Results In treatment group and control group,the effective rate was 45.2% and 43.3% respectively;and the disease control rate was 71.0% and 66.7% respectively.The adverse reaction of two groups could be tolerated,and the tolerance and surrival quality of treatment group are higher than that of the control group.Conclusions Elderly patients with advanced lung adenocarcinoma benefit from pemetrexed as first-line treatment.Pemetrexed combined with Aidi injection can relieve toxicity of chemotherapy and improve quality of life in patients.